Form 4: Pulse Biosciences CCO Sells Shares After Option Exercise

Pulse Biosciences' Chief Commercial Officer, Kevin Patrick Danahy, executed pre-planned option exercises and subsequent sales of common stock.

Summary

• Kevin Patrick Danahy, Chief Commercial Officer of Pulse Biosciences, Inc. (PLSE), reported transactions involving the company's common stock.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025.
• On February 9, 2026, Mr. Danahy acquired 20,000 shares of Common Stock by exercising options at a price of $1.53 per share and subsequently sold 20,000 shares at a weighted average price of $21.45 per share.
• On February 10, 2026, he acquired another 20,000 shares by exercising options at $1.53 per share and sold 20,000 shares at a weighted average price of $23.52 per share.
• On February 11, 2026, he acquired a further 20,000 shares by exercising options at $1.53 per share and sold 20,000 shares at a weighted average price of $25.20 per share.
• The options were granted on September 23, 2022, to acquire up to 450,000 shares, with 25% vesting on each anniversary of the grant date.
• Following these transactions, Mr. Danahy's direct beneficial ownership of Common Stock is 43,298 shares, and he holds 365,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive indicator for the executive, demonstrating significant personal profit from vested options, which often correlates with company stock appreciation. The pre-planned nature of the transactions also mitigates potential negative interpretations.

Positives

• The Chief Commercial Officer realized significant profits by exercising stock options at a low price ($1.53) and selling the shares at substantially higher market prices (ranging from $21.45 to $25.20).
• The execution of these transactions under a Rule 10b5-1 plan indicates pre-planned activity, reducing concerns about opportunistic insider trading.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived by the market as a lack of confidence, although in this case, it's an exercise-and-sell transaction.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Form 4 filings are transactional disclosures and do not typically provide industry-wide insights. These transactions reflect individual executive compensation and trading strategies within Pulse Biosciences, Inc.

Corporate Governance

Related Party Transactions

• The reported transactions are related party dealings as they involve Kevin Patrick Danahy, an executive officer (Chief Commercial Officer) of Pulse Biosciences, Inc., exercising stock options and selling common stock.

Stakeholder Impact

• Shareholders may view the executive's profitable exercise and sale of shares as a positive sign of the company's stock performance, while also noting the executive is taking profits.
• The transactions, being pre-planned under a 10b5-1 plan, demonstrate a structured approach to executive compensation and liquidity, which can be seen positively by governance-focused investors.

Key Dates

Recommendation

While the executive is profiting significantly from option exercises and sales, these transactions were pre-planned under a Rule 10b5-1 plan. A Form 4 primarily reports insider transactions and does not provide sufficient fundamental or strategic information to warrant a strong buy or sell recommendation. The profitability for the insider is a positive signal, but further analysis of the company's financials and strategic direction is needed for a definitive investment stance.

Keywords

Pulse Biosciences, PLSE, Form 4, insider trading, stock options, executive compensation, Rule 10b5-1, Kevin Patrick Danahy, Chief Commercial Officer